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The activation of helper T lymphocytes requires the recognition of foreign
antigen in association with a self HLA class II molecule. This phenomenon is
known as HLA class II restriction (1). The polymorphic class II epitopes that are
corecognized by Th cells are functionally defined as restriction determinants
(RDs)' (2). There are three groups of HLA class II molecules: DP, DQ, and DR
(3). These molecules are expressed as heterodimeric glycoproteins on the cell
surface of immunocompetent cells and are composed of a heavy (a) and a light
(,0) chain (3). The DP and DQ regions each contain 2a and 2,0 genes, whereas
the DR region is known to encode la and 3f (at, 02, 03) genes (3). It has been
reported (see references 1, 2, 4) that RDs for Th cells are carried by each group
of class II products, namely D/DR, DP, and DQ. However, the exact molecules
carrying these RDs as well as the epitopes involved have remained poorly
characterized.
The major histocompatibility class II molecules have been defined as the
products of class II immune response (Ir) genes in experimental animals (5).
Such Ir genes determine the abilityofan individual to generate T cell-dependent
immune responses against specific antigens (5). The polymorphism of these class
II Ir genes results in genetically controlled differences in such T cell-dependent
immune responses. An important human example of class II Ir genes may be
provided by leprosy, a chronic infectious disease that is caused by Mycobacterium
leprae (6). HLA class II-linked genes are known to control the type of leprosy
that develops upon infection (reviewed in 7, 8), as well as the cell-mediated
immunereactivity against M. leprae and related mycobacteria as measured by
skin testing (7, 8). Since both leprosy type and skin test responsiveness strongly
correlate with M. leprae-specific Th cell reactivity, HLA class II Ir genes may
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regulate these Th cell responses against M. leprae antigens. If so, the mechanism
of such HLA class II Ir genes might be the differential presentation of M. leprae
antigens to Th cells by HLA class 11 RDs.
In this study we have systematically explored the nature of the RDs for M.
leprae by presenting M. leprae antigens to T cell clones (TLC) from leprosy
patients. The antigen specificity of several of these TLC has been reported
recently (9-11). The molecular localization of the RDs was determined by
inhibition studies with HLA class II-specific mAbs, whereas the polymorphism
of the RDs was analyzed by the presentation capacity of large panels of fully class
II-typed allogeneic APC . The results show that the majority of the RDs for M.
leprae reside on DR molecules and not on DP or DQ molecules. Since DR
molecules have a much higher expression than DP and DQ molecules, this result
suggests that quantitative differences in the expression of class II molecules
correlate with their function in the immune response. The same explanation
holds true for the observation that RDs on DR molecules coded by a DR4Dw 13
haplotype were located only on a subgroup of DR molecules with the highest
expression. The data also indicate that multiple distinct RDs are present on one
DR molecule.
Materials and Methods
Cells.
￿
PBMC were isolated from heparinized venous blood from three leprosy patients
(BC, R, and SC) by Ficoll-Isopaque density centrifugation (specific gravity, 1 .077 g/ml),
washed three times in HBSS (Gibco Laboratories, L. Paisley Scotland), and resuspended
in Iscove's Modified Dulbecco's Medium (IMDM; Gibco Laboratories) supplemented with
streptomycin (100,ug/ml) and penicillin (100 U/ml), both from Flow Laboratories, Inc.,
Paisley Scotland, and 10% pooled human AB serum (HS). EBV-transformed B cells(EBV-
BC) were generated from 5 X 106 autologous PBMC. Cells were frozen in 1-ml ampules
(Nunc, Roskilde, Denmark) containing 1-5 X 106 cells, 70% RPMI 1640 (Gibco Labora-
tories), 20% screened pooled human AB plasma, and 10% DMSO and were stored at
-196 0 C.
Antigen. M. leprae antigen (Dharmendra) was kindly provided by Dr. R. C. Good
(Centre for Infectious Diseases, Centers for Disease Control, Atlanta, GA). The prepara-
tion consisted of bacilli that had been isolated from human lepromas.
Antigen Reactivation and Cloning of M. leprae Reactive T Lymphoblasts.
￿
This was per-
formed as described recently (10). In brief, 5 X 106 PBMC of two tuberculoid patients
(BC and R) and one borderline lepromatous leprosy patient (SC) were restimulated in
vitro with M. leprae in IMDM supplemented with 10% HS. The cultures were incubated
for 5 d in 24-well tissue culture trays (Falcon 3047 ; Becton Dickinson & Co., Mountain
View, CA) at 37°C in a fully humidified 5% C02-air mixture. Enrichment for T cell blasts
was obtained either by Percoll (Pharmacia Fine Chemicals, Uppsala, Sweden) density
centrifugation or by extending the cultures for another 3-10 d in the presence of 10%
IL-2-containing medium (Lymfocult-T; Biotest, Serum Institute, Frankfurt, Federal Re-
public of Germany). After the isolation of the blasts, a cell suspension was made containin
five ve blasts/ml in a mixture consisting of (a) PBMC from three to four random donors (10
cells/ml, 30-Gy irradiated), (b) autologous EBV-BC (105 cells/ml, 50-Gy irradiated), and
(c) an optimal concentration of M. leprae antigen, all in IMDM supplemented with 10%
HS. This suspension was plated in 96-well, flat-bottomed microtiter plates (Falcon 3072 ;
Becton Dickinson & Co.) (0 .1 ml/well; i. e., 0.5 T lymphoblast/well) and was incubated as
described above. Growing cultures were transferred to 24-well tissue culture trays (Falcon
3047 ; Becton Dickinson & Co.) and restimulated with 1 ml/well of the cell/antigen
mixture described above. 3-4 d later IL-2 (10%) was added. After an additional 4-7 d,
the cultures were restimulated again until a minimum of 2 X 106 cells per culture wasOTTENHOFF ET AL.
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obtained. The cells were then frozen or expanded further by restimulation as described
above for 4 d, except that Leuko Agglutinine (Pharmacia Fine Chemicals) was added to
the cell/antigen mixture (final concentration, 1 ug/ml) to increase the yield of cells. This
was followed by culturing for 3-5 d in the presence of IL-2.
Proliferative Assays.
￿
104 TLC (0.05 ml) and 5 x 10' irradiated (40-Gy) autologous or
allogeneic PBMC as APC (0.05 ml) were cultured in IMDM with 10% HS with 0.1 ml of
M. leprae antigen (1/120 dilution) in 96-well, flat-bottomed microtiter plates (Greiner,
Nurtingen Federal Republic of Germany). PHA (4 ug/ml; Wellcome Diagnostics, Beck-
enham, United Kingdom) and plain IMDM were used as controls. The cultures were set
up in duplicate or triplicate and incubated as described above for 72 h. 18 h before
termination, 1 .0 ACi of ['H]-thymidine (sp act, 5.0 Ci/mmol; Radiochemical Centre,
United Kingdom) in 0 .05 ml RPMI 1640 was added. The samples were harvested on
glass-fiber filters using a semiautomatic sample harvester. [sH]Thymidine incorporation
was assessed by counting in a liquid scintillation counter (G. D. Searle & Co., Chicago,
IL). All cells had been typed for HLA-A, B, C, DR, (including DRw52 and DRw53), DQ,
and DP, as mentioned in reference 2. In addition, a number of cells were also typed for
the cellularly defined HLA-D determinants, using homozygous typing cells and primed
lymphocyte typing reagents as described in references 12 and 13 .
Monoclonal Antibodies.
￿
The mAbs used in this study were generously provided by F.
Koning (from our department), unless mentioned otherwise, and were PdV5.2 (anti-class
II monomorphic; recognizing DR, DP, and approximately half of the DQ molecules;
IgG 1), B9.12.1 (anti-class I monomorphic; IgG2a; a gift ofB. Malissen, Marseille, France),
B8 .11.2 (anti-DR monomorphic; IgG2b; also a gift of B. Malissen), 7 .3.19.1 (anti-DRw52-
like; IgG2b), SPV-L3 (anti-DQ monomorphic; IgG2a; a gift of H. Spits, Lyon, France),
B7/21 (anti-Fa or DP monomorphic; IgG; gift of F. Bach, Minneapolis, MN), IIB3 (anti-
DQw 1-like; IgG2b), TA10 (anti-DQw3; like IgM; gift ofH. Maeda, Tokyo, Japan), 109d6
(anti-DRw53-like; IgG2a; gift of R. Winchester New York, NY), IC2 (anti-class II
monomorphic; IgG2a), LDL1 (anti-DR monomorphic; IgM), Ti122 (anti-DQ mono-
morphic; IgG2a; gift of A. Ziegler, Tubingen, Federal Republic ofGermany), Genox 3.53
(anti-DQwI-like; IgG I ; gift ofJ. Bodmer, London, United Kingdom), OKT3 (anti-CD3;
purchased from Ortho Diagnostic Systems Inc., Westwood, MA), RIV-6 (anti-CD4; IgG2a;
National Institute of Public Health, Bilthoven, The Netherlands), FK18 (anti-CD8; IgG3),
FK24 (anti-CD11; IgGI), anti-Leu-7 (anti-human NK cell-like; IgM; purchased from
Becten Dickinson & Co.), and PL15 (anti-DP monomorphic; gift of R. Knowles, Sloan
Kettering, New York). All mAbs consisted of mouse-derived ascites except for Tu22,
which was the supernatant of a hybridoma culture. All mAbs are described in reference
14 .
Inhibition ofAntigen-specific TLC Proliferation by mAbs.
￿
Cultures were set up as described
above, except that the same amount of antigen was added in 0.05 instead of 0.1 ml. At
the start of the culture, 0 .05 ml IMDM with mAb was added. All mAbs were filter-
sterilized through 0.22-km filters (Gelman Sciences, Inc., Ann Arbor, MI) and tested in a
final completely saturating concentration of 1 :50-1 :200 from the original ascites.
IFN--y Assay.
￿
Culture supernatants of antigen-activated TLC as described above were
measured in duplicate for levels of IFN-,y after 90 h by a solid-phase RIA (Centocor,
Malvern, PA), by using two distinct anti-IFN-,y mAbs. The first mAb had been coupled
to polystyrene beads, the second had been labeled with "'I and was added to the first
mAb after the addition of culture supernatant and washing the beads. Unbound, labeled
mAb was then removed by washing. Bound radioactivity was determined by gamma
scintillation counting. IFN-7 concentrations of the measured samples were derived from
a standard curve and expressed as units/milliliter.
Results
Cell Surface Marker Phenotype of, and IFN--y Production by Activated TLC.
￿
To
characterize the nature of the TLC obtained, we first studied the cell surface
antigens expressed by these TLC. All TLC had the CD3+CD4+CD8- phenotype1926
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TABLE I
Activated M. Leprae-reactive T Cell Clones Produce IFN-y
M. leprae antigen was presented to six TLC and one polyclonal T lymphoblast
culture of the same patient by class 11-compatible APC in quadruplicate. Two
cultures were assayed for ['H]TdR incorporation by the T cells whereas the
supernatant of the two remaining cultures was tested for IFN-y production (see
Materialsand Methods).
and were strongly positive for HLA-DR . In contrast, the expression of DQ varied
from negative to strongly positive (data not shown).
Helper TLC are known to produce IFN-y upon antigen activation. IFN-y is a
major macrophage-activating factor and as such an important mediator for the
induction of killing of intracellular parasites such as M. leprae (15). The correla-
tion between M. leprae-induced IFN-y production in vitro and T cell-mediated
immunoresponsiveness in vivo and in vitro has been clearly established (16) . The
data presented in Table I show that the TLC tested (n, 6) and the parental
polyclonal T lymphoblast culture produce IFN-y upon activation with M. leprae.
We saw a poor correlation between proliferation and IFN-y production (p, 0.45).
Based upon the membrane-phenotypes, IFN-y production, class 11-restricted
proliferative responses to M. leprae antigens (vide infra), and the inability to
suppress other Th cell responses against M. leprae (11), the TLC described in
this paper were defined as helper TLC.
Definition of Distinct Restriction Determinants on DR Molecules Coded by a HLA-
DR4/Dw13 Haplotype. Nine M. leprae-reactive proliferative TLC of patient BC
were selected at random for further studies addressing their RD repertoire . All
these TLC were specific for distinct antigenic determinants expressed by M.
leprae, as had been determined previously (10; our unpublished observations).
The HLA class II phenotype of BC is DR3,4; Dw13; DRw52,53 ; DQw3 ; DPw1,5.
The data presented in Table II show that six of the nine TLC tested are
activated by antigen in association with DR4 or Dw13 but not DR3 related RDs.
DR4 behaves like a supertypic specificity for the cellularly defined Dw4,10,13,14,
and 15 determinants (12). These six TLC could all be inhibited completely by
the same set of HLA-DR framework (DR') reactive mAbs, but not at all by
DQ-, DP-, or class I-specific mAbs. Interestingly, a DRw53-specific mAb (I 09d6)
that has been reported (17, 18) to block completely the responses of other TLC
in these highly saturating concentrations (17, 18), did not block those M. leprae-
reactive helper TLC that clearly have to recognize a determinant on a DR
TI-C
IFN-y production
U/ml
Proliferative
(cpm x
response
10-9)
RI 1G5 1.9 0.1 14.2 0.0
RI 1 E4 40 .3 0.1 57.9 0.1
RI 2 F9 27.2 0.1 88.4 0.1
RI 3 B4 6.0 0.1 42.2 0.2
RI I F9 14.5 0.2 10.0 0.1
RI 3 E8 24.8 0.1 70.5 2.3
Polyclonal T-LB 22.4 0.1 53.7 0.1~
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FIGURE 1 .
￿
Localization of restriction determinants for M. leprae-reactive TLC on HLA-DR
molecules. Inhibition of M. leprae-induced T cell responses in the presence of autologous or
class II-compatible APC. The results shown for TLC BCV14F3 (see Table II), RIIF9, and
RI3E8 (see Table 111) are expressed as the percentage inhibition of the TLC responses against
M. leprae as calculated with the formula: (1-cpm ofTLC cultured in the presence of mAb/cpm
of TLC cultured in the absence of mAb) X 100% . SD, 510%. cpm in the absence of mAb for
VI4F3 was 31,565; for I1 F9 15,075; and for I3E8 11,885.
molecule from the DR4Dw13 haplotype. Since all these inhibition patterns were
identical, only one representative example (TLC VIM) is shown in Fig. 1 .
These blocking studies indicate that the RDs for these TLC have to be located
on the DR+DRw53- molecules and not on the DR-DRw53+ ones, which are low
in expression compared with the DR+DRw53- molecules (19, 20). The
DR+DRw53- molecules carry the DR4 and the DR4-related Dw allospecificities
(19-24). Biochemical studies (19-24) have shown the presence of only one such
a DR+DRw53- (a#,) complex in DR4Dw13 homozygous individuals, which
implies that the RDs also have to reside on that same molecule .
We saw five different clusters of TLC responses that were reproducible. In
the case of TLC IIID4, antigen-induced responses closely followed the presence
of the DR4 epitope on the APC (p = 0.002) irrespective of the corresponding
Dw phenotype. The responses of the other five TLC (Table 11, left five) were
closely associated with the Dw13 determinant. These latter TLC could not be
activated by APC expressing the other DR4-associated Dw specificities, namely
Dw4, Dw10, and Dw14. No Dw15' APC were tested since this specificity is only
seen in Oriental populations (12) . In this group of five TLC, we saw four related
but distinct Dw13-associated clusters; in one cluster, (V15F7; V14173) TLC
responsiveness followed exactly the presence ofthe Dw 13 specificity on the APC,
whereas in the other three cases, respectively, six (V15B11), five (IIIE3), and
rLC mAb SPECIFICITY -20
PcIV5.2 DR "DP"DQ
-88.11.2 DR
7.3.19.1 DRw52-like
109d6 DRw53-like
BC YI4F3 89.12.1 HLA-class I
SPV-L3 DO
B7/21 DP
IIB3 DQw1-like
TA10 DQw3-like
PdV51 DR" DP"DQ
IC2 DR" DP" DQ
0.11 OR
R 11F9 8 LD111 DR
73.19.1 DRw52-like
89.12.1 HLA-class 1
SPV-L3 DO
87/21 DP
PdV5.2 DR " DP " Da
IC2 DR " Op " DQ
R 13 E8 LD1.i
DR
73.19.1 DRw52-like
89.12.1 HLA-class l
SPV-L3 DO
87/21 DPOTTENHOFF ET AL.
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three (VI1E8) of the seven Dw13' APC could activate these TLC in the presence
of optimal concentrations of M. leprae antigens. These latter three different
clusters thus are associated with, but clearly not identical to, the Dw specificity .
It should be mentioned that TLC restricted either by the serologically defined
DR specificities or by Dw specificities subdividing the associated DR antigen have
been described also for other haplotypes, including DR4Dwl4 (25) and
DR2Dw12 (26) . However, the RDs described in these and other studies corre-
lated with the known Dw types and did not detect an additional Dw-related RD
heterogeneity, as shown in the present study.
In conclusion, our results indicate that in the DR4Dw13 haplotype both the
serologically defined DR4 and the cellularly defined Dw13 allospecificity may be
closely related to if not identical with RDs for M. leprae. In addition, five TLC
define four Dw13-related clusters, most probably representing four distinct
Dw 13-associated RDs . All RDs in this haplotype were situated on the DR'-
DRw53- (a#,) molecule and not on the DR-DRw53+ (a03) one, which is low in
expression compared with the a#, molecule.
Definition of Different Restriction Determinants on DR Molecules Coded by HLA-
DR3 and -DR2 Haplotypes. To determine the repertoire of RDs for M. leprae
on molecules expressed by DR3, DRw52 (DQw2) haplotypes, we studied a
number of TLC derived from patient R (class 11 phenotype: DR2,3; DRw52;
DQw1,2 ; DPw5), as well as the three TLC of patient BC not restricted by
DR4Dwl3-associated determinants. So far, all TLC from patient R have been
found to recognize distinct M. leprae protein antigens (9) .
As shown in Table II, the three TLC of BC (IIIE10, 112F10, and I14A4)
recognized different determinants on several but not all DR3+ APC. In addition,
TLC 114A4 was activated by a DR3- APC, which was derived from a DR4Dw13
haplotype-identical sibling. In Table III are shown four TLC from patient R
that responded to M. leprae plus DR3+ APC. Four other TLC showed an identical
pattern and therefore are not shown. Inhibition studies revealed that all TLC of
BC and R restricted by DR3-associated determinants could be inhibited by mAbs
reactive with DR framework (DR') structures, as well as by mAb 7 .3 .19.1, which
recognizes a DRw52-like specificity. In Fig. 1 one representative example for
these TLC is shown (RI 1 F9). No, or only weak inhibition was seen in case of DP,
DQ, or class I-specific mAbs. Using another DR-specific mAb, the RDs of the
TLC from patient R, which in panel as well as in the mentioned inhibition studies
reveal identical patterns, could be subdivided on the base of differences in
inhibition (data not shown here). Taken together, these results indicate that all
DR3-related RDs reside on molecules that carry both DR- and DRw52-like
determinants.
To determine the RDs for M. leprae expressed by class 11 molecules on DR2,
DQw I' APC, TLC of patient R and of patient SC (class 11 phenotype: DR2,4;
Dw13; DRw53 ; DQw2,3) were studied in more detail. The results are summa-
rized in Tables III and IV . It is evident from Table III that several TLC are
restricted by DR2-associated determinants. Only 4 of 14 TLC, all displaying a
similar DR2-associated pattern, are shown in the table. Although only one Dw12'
APC could be tested, the TLC responses seem to be associated with the DR2
specificity rather than with the Dw2 or 12 specificities on the APC.1930
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TABLE IV
HLA-DR-associated Restriction ofM. leprae-reactive TLC
* M. leprae antigen was presented by allogeneic APC to TLC derived from leprosy patient SC. The
HLA class II phenotype of this patient wasDR2,4; Dw13; DRw53; DQw2,3 .
The TLC-APC combinations in which the analyzed class lI antigen was shared between TLC and
APC were compared with regard to the observed TLC proliferative responses to the responses
observed in the TLC-APC combinations mismatched for that class II antigen. The significance of
the results are given as Fisher's exact p values. Positive responses ranged from 1.2 ± 0.2-40.2 ±
0.4 cpm; negative responses ranged from 0.0 t 0.0-0.2 i . 0.0 cpm.
§These TLC were also tested for sharing of DR4, DQw2, DQw3, DRw53, and DPw4 antigens; all
p values were >0.25 (data not shown).
u Since the T cell donor was not typed for DP, all known DP (wl-7) allospecificities were analyzed
in the same way. Thep values obtained varied between 0.30 and 0.72, as summarized in the table.
Also, the polyclonal T cell line of this patient responded equally well to
Dw2+Dw 12- as to Dw2-Dw 12+ APC (data not shown here). The results for three
TLC of patient SC that were (also) restricted by DR2-associated determinants in
panel studies are summarized in Table IV (II2F5, II2F9, 112112). The anti-
gen specificity of these TLC was described recently (11) . In this case, no
DR2+Dw2-Dw 12+ APC were tested. Inhibition studies performed with these
TLC from patient R and SC pointed out that all DR framework-reactive mAb
(n, 4) completely inhibited the proliferation of these TLC, whereas we saw no
inhibition in the case of mAbs specific for DP, DQ, class I, or DRw52. Therefore,
only one representative example is shown in Fig. 1 (RI3E8).
Recently, evidence has been presented (26) suggesting that the DR2 determi-
nant is situated on DRaf, complexes that are distinct from those carrying the
Dw2/ 12 determinants, namely the a02 complexes. Moreover, RDs for strepto-
coccal as well as measles antigens displayed a preference for the a(02 and not the
aO, complex (26, 27). Our data suggest that in contrast, the M. leprae RDs show
a preference for the a,Q, complex.
In conclusion, our results suggest that also in the case of the class II molecules
expressed by DR2, (DQw l) haplotypes, RDs for M. leprae reside almost exclu-
sively on DR molecules. It is likely that most RDs for M. leprae are located on
the DRao, molecules that express the DR2 but not the Dw2 or Dw12 determi-
nants.
New Restriction Determinants Defined on DQ and DP Molecules. TLC 13F10,
shown in the last column of Table III, was activated only by M. leprae plus
TLC*
HLA class II
antigen
analyzed
Effect of sharing or mismatching of classII
and APC on T cell responsiveness$
Class II antigen shared: yes yes no
TLC response observed: yes no yes
antigen between T cell
no value no p
SC112B2 DR2§ 5 0 0 18 0.00006
SC112F5 DR21 3 0 0 12 0.004
SC112F9 DR2§ 3 0 0 12 0.004
SC112F6 DR2 1 4 12 6 0.176
DR4 5 0 8 10 0.076
DQw2 6 4 7 6 1.000
DQw3 10 2 3 8 0.020
DRw53 13 2 0 8 0.0002
DPw1-71 >0.301932
100
FIGURE 2.
￿
Inhibition patterns of an HLA-DQ and an HLA-DP-restricted M. leprae-reactive
TLC. Inhibition of M. leprae-induced T cell responses in the presence of autologous or class
II-compatible APC. Theresults areexpressed as the percentage inhibition (see legend to Fig.
1). SD, <<-10%. cpm in the absence of mAb for 13F10 were 40,545 and for II2F6 5,400.
autologous but not allogeneic APC (n, 32; only 17 are shown), including cells
derived from individuals from the same ethnic group. Inhibition studies showed
that antigen-induced responses were inhibited completely by an mAb reactive
exclusively with DQ molecules (SPV-L3; Fig. 2A), and by only one of the two
mAbs reactive with monomorphic class II determinants. We sawpartial inhibition
in the case of mAb Tii 22 and genox 3.53, reactive respectively with a mono-
morphic DQ and a DQw1 determinant. The weak inhibition seen in the case of
mAb LD1 .1 may be due to crossreactivity with DQ determinants. In conclusion,
this TLC recognizes a RD on DQ molecules that is only expressed by autologous
APC, and not by the 32 other allogeneic APC.
TLC II2F6, shown in Table IV, recognizes M. leprae in association with a
variety of allogeneic APC. Positive responses correlated best with the sharing of
the DRw53 specificity between APC and TLC (p = 0.0002), less significantly so
with DQw3 (p = 0.02), and not at all with DR2 or DR4. Since this T cell donor
had not been typed for DP, we analyzed the T cell responses against all known
DP allospecificities on the APC tested, namely DPwl-7 . None of the DP deter-
minants were associated with T cell responsiveness (p = 0.30), excluding an
association between the RD and one of the known DP specificities. Unexpectedly,
however, blocking studies revealed that the RD is situated on a DP molecule,
since mAb 137/21 could inhibit proliferation completely (Fig. 213) . mAb PL 15,
which is also directed against DP determinants, showed only marginal inhibition .
In conclusion, the RD recognized by this TLC is situated on a DP molecule,
does not correlate with currently known DP allospecificities, and is frequently
expressed among the population of APC tested (13 of 23).
Alloreactivity of Class II-restricted M. leprae-reacted TLC.
￿
Three regular class
II-restricted M. leprae-reactive TLC were found to crossreact with some but
not all allogeneic APC in the absence of antigen. These TLC were BC112F10,
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TLC mAb SPECIFICITY -20
%INHIBITION
0 50
A PcIV5.2 DR+OP"OQ
IC2 DR-DP-DO
88.11 2 OR 777 -71
R 13 F10 LD1.1 OR
73.19.1 ORw52-like
139.12.1 HLA-class I
SPV-L3 DO
TO22 OQ
Genox 3.53 DQw1
11133 DOW1-like
_B
PdV5.2 OR -OP-011
88.11.2 OR
7.3.19.1 ORw52- like
SC 112 F6 89.12.1 HLA-class I
SPV-L3 OQ
II B3 OQw1-like
TA 10 0Qw3-like
I7777//777.
109d6 ORw53-like
87/21 DP
PL 15 OP fOTTENHOFF ET AL.
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shown in Table 11 (APC 27); R12G4 (Table 111, APC 13 and 14); and R13F10
(Table 111, APC 17). One of these three TLC, namely RI2G4, was analyzed in
more detail by means of panel and inhibition studies, and was found to recognize
a DPw4-related allodeterminant (our unpublished observations).
Discussion
In this report, we have defined the HLA class 11 molecules and characterized
the polymorphic epitopes or RDs on these molecules, which in association with
M. leprae antigens, are recognized by cloned M. leprae-reactive Th lymphocytes
from leprosy patients. The molecular localization of the RDs was defined by
inhibition studies with HLA class II-specific mAbs, whereas the polymorphism
of these RDs was determined in panel studies with fully class 11-typed allogeneic
APC. The reason why we were interested in defining these RDs is based on two
facts. First, polymorphic HLA class 11-linked Ir genes have been shown to
determine T cell-mediated immune responsiveness against M. leprae and related
mycobacteria in vivo (reviewed in 7, 8), as well as the type of leprosy that develops
upon infection in susceptible individuals (7, 8). Second, MHC class 11 molecules
are involved in the restriction and regulation of antigen presentation to Th cells
and as such have been defined as the products of class II Ir gene products
(references 5, 8). We reasoned therefore that the Ir genes that regulate the in
vivo immune response against M. leprae may actually code for RDs that restrict
and regulate the (in vitro) presentation of M. leprae antigens to Th cells. The
definition of such RDs is crucial for the unraveling of the mechanism of this
HLA disease association.
Our first important observation was that the majority of the RDs for M. leprae
are located in the polymorphic domains of HLA-DR molecules, and not on DP
or DQ molecules. Of course, one has to be cautious in drawing general conclu-
sions from data obtained from three patients. However, we have also studied the
restriction of polyclonal Th cell lines from 22 leprosy patients that show a similar
preferential DR restriction (Ottenhoff, T. H. M ., D. G. Elferink, J. Kobesson,
D. L. Leiker, R. F. M . Lai, A. Fat, and R. R. P. de Vries, manuscript submitted
for publication). Thus DR molecules play a major role in the presentation of M.
leprae antigens to T cells from leprosy patients. Since these same molecules also
express the DR allospecificities that are associated with the regulation of immune
responses against M. leprae in vivo (vide supra), it is very likely that those HLA-
DR-coded RDs are closely associated with, if not identical to, the M. leprae-
specific HLA class II Ir gene products. It has been established that the expression
of DR molecules is much stronger than that of DP (14, 28, 29) and DQ (14, 29)
molecules. Quantitative differences in the expression of the different class 11
molecules can result in profound differences in their function in immune re-
sponses, as has been shown by studies of mice (30). Recently, we have presented
evidence that human polyclonal T cell responses to PPD of Mycobacterium
tuberculosis are restricted preferentially by those DR molecules that show the
highest expression on APC (31). However, the precise molecular localization of
RDs is only possible with the use of cloned T cells, as was done in the present
study. In the case of DR molecules in DR4+ cells, two types of DR molecules are
expressed, namely DR+DRw53- (a0,) and DR-DRw53+ (03) molecules (19-24),1934
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the DR4 02 gene being a pseudogene (32). Our inhibition studies localized the
M. leprae RDs only on the ao, and not on the a,Q3 molecules. These DR4 ao,
molecules carrying the M. leprae RDs have a significantly higher expression than
the DR4 a03 molecules (19, 20), which would fit with the preferential localization
of M. leprae RDs on DR and not on DP or DQ molecules as a consequence of
quantitative differences in the expression of class 11 molecules.
In the case of DR molecules expressed by DR2+ cells, qualitative rather than
quantitative differences between different DR molecules may also be of impor-
tance for the localization of RDs for M. leprae. Recently, two distinct DR2-
related DR molecules were described, one probably carrying the DR2 determi-
nant (a0,), the other one expressing the Dw2 or Dw12 specificities (a02; 26). It
was shown that both molecules could stimulate allogeneic mixed lymphocyte
cultures as well as presenting antigen to Th cells. Of interest here is that in this
as well as in a second study (27) the RDs for respectively, streptococcal and
measles virus antigens were mapped mainly to the a02 and not to the ao,
molecules. Our results suggest that RDs for M. leprae also may show a preference
for the a,0, complex. In the case of DR molecules expressed by DR3+ cells,
inhibition studies (31) showed that the RDs for M. leprae were situated on DR
molecules expressing both DR- and DRw52-like determinants. These DR+-
DRw52+ molecules have been described previously and have been shown to
carry RDs for M. tuberculosis as well (31) .
Because information concerning the sequences of several DR01 alleles studied
by us has recently become available (19-23, 34, 35), we were in a unique position
to analyze the relation between structure and function of HLA class II molecules,
notably the relationship between allodeterminants and determinants restricting
antigen presentation. Comparison of the sequences of DR01 cDNA clones from
Dw4+, Dw 13+ , and Dw 14+ individuals has revealed only one to three different
nucleotides that result in amino acid substitutions between residues 71-86 of the
first domain, which are likely to be situated on the outer face of the DR01
molecule (33, 34). These DR01 differences may explain completely the Dw allelic
differences (19-24). Our results show (see Table II) that one of six M. leprae-
reactive TLC restricted by the DR4+ haplotype recognized a M. leprae antigen
in association with an RD that was closely associated with DR4, and not related
to the Dw specificity of the APC, whereas the other five were restricted by
determinants associated with the Dw specificity of the TLC, namely Dw13 .
Therefore, these five TLCs can distinguish one (Dw 13 vs. Dw 14, see reference
33) to three (Dw13 vs. Dw4, see reference 33) amino acid differences between
DRao, molecules like alloreactive donors (33, 34). However, four of the five
TLC restricted by a Dw13-associated determinant clearly showed a distinct
restriction specificity in the panel studies . Although we cannot exclude the
possibility that differences in antigen processing might result in the four different
Dw13-associated clusters, we consider such a highly antigen-specific processing
defect an unlikely explanation . Therefore, we think that the four distinct Dw13-
associated restriction specificities defined by these five M. leprae-reactive TLCs
represent in all probability four different RDs on one DR a/3, molecule . The
fact that only two of the five TLCs show an identical restriction specificity
suggests that the potential of RDs on this DR a/3, molecule is much larger .OTTENHOFF ET AL.
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Because all the M. leprae-reactive TLC tested thus far recognize different M.
leprae antigenic determinants (epitopes), the different processed peptides carry-
ing these epitopes might bind to distinct class II determinants ("desetopes") with
their "agretopes" (35). This differential binding might then give rise to the
expression of different "histotopes" recognized by the T cell receptor .
Whatever the mechanism generating it, it is clear from our data that a minimal
difference between class II molecules (only one AA residue between the DRa0,
molecules of Dw13 vs. Dw14) combined with different antigens may result in an
almost infinite number of RDs. This confirms data from experimental animals
and implies that conformational changes of class II molecules are important in
the generation of RDs (36, 37).
A third conclusion is that these M. leprae-specific TLC define novel epitopes
on DP and DQ molecules, which may be more relevant than those detected with
alloantibodies, allospecific T cells, or biochemical techniques. Although M.
leprae-reactive Th cells are apparently mainly restricted by determinants on DR
molecules, some clones do use RDs on DP and DQ molecules. Thus one TLC
recognized a RD on a DP molecule notassociated with a known DP allospecificity.
Even more interesting was that another TLC (R13FI0) defined a RD on a DQ
molecule which was only expressed by autologous APC but not by 32 allogeneic
APC. The DQ region may therefore be much more polymorphic than assumed
thus far.
This may well be biologically quite important. In fact, the low frequency of
DP- and DQ-restricted, M. leprae-reactive helper TLC seen by us may well be a
considerable underestimate of in vivo situations, because of an in vitro selection
for clones restricted by class II molecules with the highest expression on the
APCs used for restimulation. Moreover, not all T cells are Th cells and it may
be that for suppressor T cells, qualitative differences in expression of HLA class
11 molecules are more important.
Finally, we saw that several M. leprae-reactive, class II-restricted helper TLC
showed crossreactivity with a minority of allogeneic APC in the absence of
antigen. Such a dual specificity has been described extensively for murine TLC,
and recently (38) also for a human TLC. One of the three TLC displaying this
dual specificity (namely RI2G4) was studied in more detail, and was found to
crossreact against a DPw4-like class II determinant. However, we could not
extend our studies of this interesting phenomenon because both the original
TLC as well as subclones derived from that TLC lost their antigen specificity
upon further expansion of the cultures. In our hands, this has been an exception
for M. leprae-reactive TLC. Whether this loss of antigen specificity preceded by
the appearance of alloreactivity has any biological significance, and if so what,
remains to be seen.
Summary
MHC class II molecules carry the restriction determinants (RDs) for antigen
presentation to antigen-specific Th lymphocytes. This restriction of T cell acti-
vation endows those molecules with a key role in the induction and regulation
of antigen-specific immune responses. Moreover, class II molecules are the
products of class 11 immune response (Ir) genes. The polymorphism of these Ir1936
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genes leads to genetically controlled differences in immuneresponsiveness be-
tween different individuals. An important human example is leprosy, in which
HLA class 11-linked Ir genes determine the immune response against Mycobac-
terium leprae, the causative organism of the disease. Since the immune response
against M. leprae is entirely dependent on Th cells, the HLA class II-linked Ir
gene products may well regulate the immune response by controlling the pres-
entation of M. leprae antigens to Th cells. We therefore have investigated the
HLA class II RD repertoire ofM. leprae-reactive Th cell clones (TLC) by means
of extensive panel and inhibition studies with fully class II-typed allogeneic APCs
and well-defined HLA class II-specific mAbs . The TLC studied (n, 36) prolif-
erated specifically towards M. leprae, produced IFN--y upon activation, and had
the CD3 +CD4+CD8- phenotype.
The results show in the first place that the majority of the RDs for M. leprae
reside on DR and not on DP or DQ molecules. This indicates a major role for
DR molecules in the immune response to M. leprae and suggests that these
molecules are the main products of M. leprae-specific Ir genes. Furthermore,
since the expression of DR molecules is much stronger than that of DP and DQ
molecules, these findings suggest that the localization of RDs for M. leprae on
class II molecules correlates with the quantitative expression of these molecules.
The observation that the RDs on DR molecules coded by a DR4 haplotype were
situated only on those DR molecules that are known to be highest in expression
can be explained in the same way.
Second, four distinct RDs related with but not identical to the Dw13 allode-
terminant were carried by the DR+DRw53 - (a0,) molecules of a DR4Dw13
haplotype. Since the known amino acid residue differences between the allelic
DR4 related Dwo, chains cannot explain the observed RD-polymorphism, this
observation suggests that multiple distinct RDs unique for the DR4Dw 13 hap-
lotype are expressed by these molecules.
Only 2 of 36 TLC were not restricted by DR. One of these TLC recognized
a new DP determinant, whereas the other TLC defined a remarkably poly-
morphic RD on a DQ molecule, which was distinct from the known DQ-related
allospecificities. These TLC therefore define novel and functionally relevant
polymorphisms on class II molecules. Finally, 3 of the 36 TLC reacted also with
a restricted number of allogeneic APC in the absence of M. leprae antigen,
indicating crossreactivity between self class 11 RD in combination with M. leprae
antigens and allodeterminants.
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